DOCSLIB.ORG

T. +972-49960595 Email: [email protected] USA: T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
T. +972-49960595 Email: Info@Bioind.Com USA: T Name Cat# Description Size A Size B NameName Cat#Cat # DescriptionDescription SizeSize AA SizeSize BB CYTOKINES AND CYTOKINES GROWTH AND GROWTHFACTORS FACTORS Activin A 30-T-569 Recombinant Human Activin-A 2µg 10µg Activin A Plant-Active 30-T-414 Recombinant Human Activin-A Active 1ug 5ug Activin A HEK-Active 30-T-078 Recombinant Human Activin-A HEK-Active 2ug 10ug Activin A Plant 30-T-052 Recombinant Human Activin-A, Plant 2µg 10µg Activin B Active 30-T-057 Recombinant Human Activin-B Active 2ug 10ug Activin B 30-T-058 Recombinant Human Activin-B 2µg 10µg Activin A, Active 30-T-145 Recombinant Human Activin-A, Active 2µg 10µg mActivin A 30-T-146 Recombinant Mouse Activin-A 2µg 10µg rActivin A 30-T-147 Recombinant Rat Activin-A 2µg 10µg ACVRL1 30-T-920 Recombinant Human Activin A Receptor Type II-Like 1 2ug 10ug Acrp30 30-T-024 Human Adiponectin 2µg 10µg Acrp30 30-T-280 Recombinant Human Adiponectin 5µg 25µg Acrp30 His 30-T-433 Recombinant Human Adiponectin, His tag 10µg 50µg Acrp30 (108-244) 30-T-073 Recombinant Human Adiponectin (108-244 a.a.) 5µg 25µg Acrp30 HEK 30-T-434 Recombinant Human Adiponectin glycosilated, HEK 2µg 10µg Acrp30 HMW 30-T-764 Recombinant Human Adiponectin glycosilated, HMW Rich 2µg 10µg Acrp30 Tri 30-T-233 Recombinant Human Adiponectin Trimeric Form 2µg 10µg mAcrp30 HEK 30-T-435 Recombinant Mouse Adiponectin glycosilated, HEK 2µg 10µg mAcrp30 His 30-T-537 Recombinant Mouse Adiponectin, His tag 5µg 25µg mAcrp30 Tri 30-T-247 Recombinant Mouse Adiponectin Trimeric Form 2µg 10µg pAcrp30 HEK 30-T-696 Recombinant Porcine Adiponectin glycosilated, HEK 2µg 10µg rACRP30 30-T-831 Recombinant Rat Adiponectin 2ug 10ug gAcrp30 30-T-615 Recombinant Human Adiponectin Globular 5µg 25µg gAcrp30 His 30-T-277 Recombinant Human Adiponectin Globular, His tag 2µg 10µg mgAcrp30 30-T-432 Recombinant Mouse Adiponectin Globular 10µg 50µg AIF1 30-T-697 Recombinant Human Allograft Inflammatory Factor 1 2µg 10µg AIF1L 30-T-007 Recombinant Human Allograft Inflammatory Factor 1 Like 5µg 20µg AITR 30-T-925 Recombinant Human AITR 2ug 10ug AITRL 30-T-076 Recombinant Human AITRL 5µg 20µg AITRL His 30-T-317 Recombinant Human AITRL, His Tag 5µg 20µg AITRL, T7 30-T-807 Recombinant Human AITRL, T7 Tag 2µg 10µg ANGPT1 30-T-074 Recombinant Human Angiopoietin-1 5µg 20µg ANGPTL2 30-T-765 Recombinant Human Angiopoietin-like Protein 2 2µg 10µg ANGPTL3 30-T-248 Recombinant Human Angiopoietin-like Protein 3 2µg 10µg ANGPTL3 HEK 30-T-766 Recombinant Human Angiopoietin-like Protein 3, HEK 2µg 10µg ANGPTL3 (243-460) 30-T-902 Recombinant Human Angiopoietin-like Protein 3, (243-460 a.a.) 5µg 20µg ANGPTL4 30-T-249 Recombinant Human Angiopoietin-like Protein 4 2µg 10µg ANGPTL4 HEK 30-T-698 Recombinant Human Angiopoietin-like Protein 4, HEK 2µg 10µg ANGPTL6 30-T-832 Recombinant Human Angiopoietin-like Protein 6 2µg 10µg mANGPTL7 30-T-914 Recombinant Mouse Angiopoietin-like Protein 7 1µg 5µg APOA1 30-T-750 Recombinant Human Apolipoprotein A-I 20µg 100µg APOA1, His 30-T-661 Recombinant Human Apolipoprotein A-I, His Tag 20µg 100µg APOA1 30-T-037 Human Apolipoprotein A-I 20µg 100µg mAPOA1 30-T-891 Recombinant Mouse Apolipoprotein A-I 5µg 20µg APOA2 30-T-038 Human Apolipoprotein A-II 20µg 100µg APOA5 HEK 30-T-025 Recombinant Human Apolipoprotein A-V, HEK 2µg 10µg APOA5 30-T-767 Recombinant Human Apolipoprotein A-V 2µg 10µg APOE3 30-T-874 Recombinant Human Apolipoprotein E3 100µg 500µg APOL4 30-T-785 Recombinant Human Apolipoprotein L 4 2µg 10µg APRIL 30-T-815 Recombinant Human APRIL 5µg 20µg mAPRIL 30-T-803 Recombinant Mouse APRIL 5µg 20µg AREG 30-T-041 Recombinant Human Amphiregulin 10µg 50µg Clusterin 30-T-278 Recombinant Human Apolipoprotein-J 2µg 10µg Clusterin 30-T-548 Human Apolipoprotein-J 2µg 10µg Clusterin His 30-T-814 Recombinant Human Apolipoprotein-J, His Tag 5µg 20µg rClusterin 30-T-437 Recombinant Rat Apolipoprotein-J 2µg 10µg k9Clusterin 30-T-549 Recombinant Canine Apolipoprotein-J 2µg 10µg k9Clusterin HEK 30-T-618 Recombinant Canine Apolipoprotein-J, HEK 2µg 10µg APOC1 30-T-812 Recombinant Human Apolipoprotein C-I 2µg 10µg APOD 30-T-547 Recombinant Human Apolipoprotein-D 2µg 10µg APOD, HEK 30-T-768 Recombinant Human Apolipoprotein-D, HEK 2µg 10µg APOD GST 30-T-652 Recombinant Human APO-D GST Tag 2µg 5µg APOH 30-T-189 Recombinant Human Apolipoprotein-H 2µg 10µg T. +972-49960595 Email: [email protected] USA: T. 8603162702 Email: [email protected] www.bioind.com T. 972+49960595 Email: [email protected] USA: T. 8603162702 Email: [email protected] www.bioind.com Name Cat# Description Size A Size B APOM 30-T-715 Recombinant Human Apolipoprotein-M 2µg 10µg APOM HEK 30-T-026 Recombinant Human Apolipoprotein-M, HEK 2µg 10µg Artemin 30-T-306 Recombinant Human Artemin 5µg 20µg BD 1 30-T-564 Recombinant Human Beta Defensin -1 5µg 20µg mBD 1 30-T-044 Recombinant Mouse Beta Defensin -1 5µg 20µg rBD 1 30-T-062 Recombinant Rat Beta Defensin -1 5µg 20µg BD 2 30-T-571 Recombinant Human Beta Defensin -2 5µg 20µg mBD 2 30-T-035 Recombinant Mouse Beta Defensin -2 5µg 20µg BD 3 30-T-461 Recombinant Human Beta Defensin -3 5µg 20µg mBD 3 30-T-036 Recombinant Mouse Beta Defensin -3 5µg 20µg rBD 3 30-T-063 Recombinant Rat Beta Defensin -3 5µg 20µg BD 4 30-T-599 Recombinant Human Beta Defensin -4 5µg 20µg rBD 4 30-T-066 Recombinant Rat Beta Defensin -4 5µg 20µg BD5 30-T-804 Recombinant Human Beta Defensin -5 5µg 20µg BDNF 30-T-207 Recombinant Human Brain-Derived Neurotrophic Factor 2µg 10µg BDNF, His 30-T-881 Recombinant Human Brain-Derived Neurotrophic Factor, His Tag 5µg 20µg mBDNF 30-T-919 Recombinant Mouse Brain-Derived Neurotrophic Factor 2µg 10µg proBDNF 30-T-014 Recombinant Human Precursor Brain-Derived Neurotrophic Factor 2µg 10µg BAFF 30-T-307 Recombinant Human BAFF (BLyS) 5µg 20µg BAFF His 30-T-545 Recombinant Human BAFF (BLyS), His Tag 5µg 20µg BAFF Plant 30-T-054 Recombinant Human BAFF (BLyS), Plant 1ug 5ug BAFF R 30-T-429 Recombinant Human BAFF (BLyS) Receptor 10µg 50µg BMPR1A 30-T-380 Recombinant Human Bone Morphogenetic protein Receptor-1A 2µg 10µg BMPR1B 30-T-897 Recombinant Human Bone Morphogenetic protein Receptor-1B 2µg 10µg BMP2 30-T-261 Recombinant Human Bone Morphogenetic protein-2 2µg 10µg BMP2 HEK 30-T-080 Recombinant Human Bone Morphogenetic protein-2, HEK 2µg 10µg BMP2 Mono 30-T-627 Recombinant Human Bone Morphogenetic protein-2 Monomer 5µg 20µg BMP3 30-T-937 Recombinant Human Bone Morphogenetic protein-3 10µg 50µg BMP4 30-T-361 Recombinant Human Bone Morphogenetic protein-4 2µg 10µg BMP4 Active 30-T-081 Recombinant Human Bone Morphogenetic protein-4 Active 2µg 10µg BMP5 30-T-660 Recombinant Human Bone Morphogenetic protein-5 5µg 20µg BMP6 30-T-754 Recombinant Human Bone Morphogenetic protein-6 2µg 10µg BMP7 30-T-333 Recombinant Human Bone Morphogenetic protein-7 2µg 10µg BMP7 His 30-T-629 Recombinant Human Bone Morphogenetic protein-7 His Tag 10µg 50µg BMP7 CHO 30-T-276 Recombinant Human Bone Morphogenetic protein-7, CHO 2µg 10µg BMP7 Plant 30-T-039 Recombinant Human Bone Morphogenetic protein-7, Plant 2µg 10µg BMP7 HEK 30-T-082 Recombinant Human Bone Morphogenetic protein-7, HEK 1ug 5ug BMP8B 30-T-830 Recombinant Human Bone Morphogenetic protein-8b 5µg 20µg BMP13 30-T-938 Recombinant Human Bone Morphogenetic protein-13 10µg 50µg b NGF 30-T-579 Recombinant Human beta Nerve Growth Factor 5µg 20µg b NGF CHO 30-T-246 Recombinant Human beta Nerve Growth Factor, CHO 5µg 20µg b NGF HEK 30-T-079 Recombinant Human beta Nerve Growth Factor, HEK 5µg 20µg mb NGF 30-T-581 Recombinant Mouse beta Nerve Growth Factor 5µg 20µg mb NGF 30-T-440 Mouse beta Nerve Growth Factor 5µg 20µg ProNGF 30-T-426 Recombinant Human Pro-Nerve Growth Factor 2µg 10µg BNP 30-T-327 Recombinant Human B-type Natriuretic Protein 2µg 10µg BNP His 30-T-605 Recombinant Human B-type Natriuretic Protein His Tag 2µg 10µg BNP 30-T-369 Human B-type Natriuretic Protein 10mg 25mg BST2 30-T-059 Recombinant Human Bone Marrow Stromal Cell Antigen 2 2µg 10µg BTC 30-T-330 Recombinant Human Betacellulin 5µg 20µg BTC His 30-T-077 Recombinant Human Betacellulin, His Tag 2µg 10µg mBTC 30-T-131 Recombinant Mouse Betacellulin 5µg 20µg bBTC 30-T-406 Recombinant Bovine Betacellulin 5µg 20µg CDNF 30-T-167 Recombinant Human Cerebral Dopamine Neurotrophic Factor 5µg 20µg mCDNF 30-T-729 Recombinant Mouse Cerebral Dopamine Neurotrophic Factor 5µg 20µg rCDNF 30-T-730 Recombinant Rat Cerebral Dopamine Neurotrophic Factor 5µg 20µg CLCF1 30-T-071 Recombinant Human Cardiotrophin-Like Cytokine Factor 1 5µg 20µg CNTF 30-T-272 Recombinant Human Ciliary Neurotrophic Factor 5µg 20µg CNTF His 30-T-573 Recombinant Human Ciliary Neurotrophic Factor, His Tag 5µg 20µg mCNTF 30-T-139 Recombinant Mouse Ciliary Neurotrophic Factor 5µg 25µg rCNTF 30-T-654 Recombinant Rat Ciliary Neurotrophic Factor 5µg 25µg rCNTF His 30-T-926 Recombinant Rat Ciliary Neurotrophic Factor, His Tag 2µg 10µg CNTFR 30-T-883 Recombinant Human Ciliary Neurotrophic Factor Receptor 5µg 25µg CSF2RA 30-T-796 Recombinant Human GM-CSF Receptor Alpha 5µg 20µg CSF2RB 30-T-928 Recombinant Human GM-CSF Receptor Beta 2µg 10µg T. +972-49960595 Email: [email protected] USA: T.
Load more

Recommended publications
  • RT² Profiler PCR Array (384-Well Format) Human Apoptosis 384HT
    RT² Profiler PCR Array (384-Well Format) Human Apoptosis 384HT Cat. no. 330231 PAHS-3012ZE For pathway expression analysis Format For use with the following real-time cyclers RT² Profiler PCR Array, Applied Biosystems® models 7900HT (384-well block), Format E ViiA™ 7 (384-well block); Bio-Rad CFX384™ RT² Profiler PCR Array, Roche® LightCycler® 480 (384-well block) Format G Description The Human Apoptosis RT² Profiler PCR Array profiles the expression of 370 key genes involved in apoptosis, or programmed cell death. The array includes the TNF ligands and their receptors; members of the bcl-2 family, BIR (baculoviral IAP repeat) domain proteins, CARD domain (caspase recruitment domain) proteins, death domain proteins, TRAF (TNF receptor-associated factor) domain proteins and caspases. These 370 genes are also grouped by their functional contribution to apoptosis, either anti-apoptosis or induction of apoptosis. Using real-time PCR, you can easily and reliably analyze expression of a focused panel of genes related to apoptosis with this array. For further details, consult the RT² Profiler PCR Array Handbook. Sample & Assay Technologies Shipping and storage RT² Profiler PCR Arrays in formats E and G are shipped at ambient temperature, on dry ice, or blue ice packs depending on destination and accompanying products. For long term storage, keep plates at –20°C. Note: Ensure that you have the correct RT² Profiler PCR Array format for your real-time cycler (see table above). Note: Open the package and store the products appropriately immediately
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002
    USOO6395889B1 (12) United States Patent (10) Patent No.: US 6,395,889 B1 Robison (45) Date of Patent: May 28, 2002 (54) NUCLEIC ACID MOLECULES ENCODING WO WO-98/56804 A1 * 12/1998 ........... CO7H/21/02 HUMAN PROTEASE HOMOLOGS WO WO-99/0785.0 A1 * 2/1999 ... C12N/15/12 WO WO-99/37660 A1 * 7/1999 ........... CO7H/21/04 (75) Inventor: fish E. Robison, Wilmington, MA OTHER PUBLICATIONS Vazquez, F., et al., 1999, “METH-1, a human ortholog of (73) Assignee: Millennium Pharmaceuticals, Inc., ADAMTS-1, and METH-2 are members of a new family of Cambridge, MA (US) proteins with angio-inhibitory activity', The Journal of c: - 0 Biological Chemistry, vol. 274, No. 33, pp. 23349–23357.* (*) Notice: Subject to any disclaimer, the term of this Descriptors of Protease Classes in Prosite and Pfam Data patent is extended or adjusted under 35 bases. U.S.C. 154(b) by 0 days. * cited by examiner (21) Appl. No.: 09/392, 184 Primary Examiner Ponnathapu Achutamurthy (22) Filed: Sep. 9, 1999 ASSistant Examiner William W. Moore (51) Int. Cl." C12N 15/57; C12N 15/12; (74) Attorney, Agent, or Firm-Alston & Bird LLP C12N 9/64; C12N 15/79 (57) ABSTRACT (52) U.S. Cl. .................... 536/23.2; 536/23.5; 435/69.1; 435/252.3; 435/320.1 The invention relates to polynucleotides encoding newly (58) Field of Search ............................... 536,232,235. identified protease homologs. The invention also relates to 435/6, 226, 69.1, 252.3 the proteases. The invention further relates to methods using s s s/ - - -us the protease polypeptides and polynucleotides as a target for (56) References Cited diagnosis and treatment in protease-mediated disorders.
    [Show full text]
  • Cross-Linking of Alpha 2-Plasmin Inhibitor to Fibrin by Fibrin- Stabilizing Factor
    Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin- stabilizing factor. Y Sakata, N Aoki J Clin Invest. 1980;65(2):290-297. https://doi.org/10.1172/JCI109671. Research Article The concentration of alpha 2-plasmin inhibitor in blood plasma is higher than that in serum obtained from the blood clotted in the presence of calcium ions, but is the same as that in serum obtained in the absence of calcium ions. Radiolabeled alpha2-plasmin inhibitor was covalently bound to fibrin only when calcium ions were present at the time of clotting of plasma or fibrinogen. Whereas, when batroxobin, a snake venom enzyme that lacks the ability to activate fibrin- stabilizing factor, was used for clotting fibrinogen, the binding was not observed. When fibrin-stablizing, factor-deficient plasma was clotted, the specific binding of alpha 2-plasmin inhibitor to fibrin did not occur even in the presence of calcium ions and the concentration of alpha 2-plasmin inhibitor in serum was the same as that in plasma. Monodansyl cadaverine, a fluorescent substrate of the fibrin-stablizing factor, was incorporated into alpha 2-plasmin inhibitor by activated fibrin-stablizing factor. All these findings indicate that alpha 2-plasmin inhibitor is cross-linked to fibrin by activated fibrin-stabilizing factor when blood is clotted. Analysis of alpha 2-plasmin inhibitor-incorporated fibrin by sodium dodecyl sulfate gel electrophoresis showed that the inhibitor was mainly cross-linked to polymerized alpha-chains of cross-linked fibrin. Cross-linking of alpha 2-plasmin inhibitor to fibrin renders fibrin clot less susceptible to fibrinolysis by plasmin.
    [Show full text]
  • 1General Introduction and Outline Glycosphingolipids, Carbohydrate
    Lipophilic iminosugars : synthesis and evaluation as inhibitors of glucosylceramide metabolism Wennekes, T. Citation Wennekes, T. (2008, December 15). Lipophilic iminosugars : synthesis and evaluation as inhibitors of glucosylceramide metabolism. Retrieved from https://hdl.handle.net/1887/13372 Version: Corrected Publisher’s Version Licence agreement concerning inclusion of doctoral thesis in the License: Institutional Repository of the University of Leiden Downloaded from: https://hdl.handle.net/1887/13372 Note: To cite this publication please use the final published version (if applicable). General Introduction and Outline Glycosphingolipids, Carbohydrate- 1 processing Enzymes and Iminosugar Inhibitors General Introduction The study described in this thesis was conducted with the aim of developing lipophilic iminosugars as selective inhibitors for three enzymes involved in glucosylceramide metabolism. Glucosylceramide, a β-glycoside of the lipid ceramide and the carbohydrate d-glucose, is a key member of a class of biomolecules called the glycosphingolipids (GSLs). One enzyme, glucosylceramide synthase (GCS), is responsible for its synthesis and the two other enzymes, glucocerebrosidase (GBA1) and β-glucosidase 2 (GBA2), catalyze its degradation. Being able to influence glucosylceramide biosynthesis and degradation would greatly facilitate the study of GSL functioning in (patho)physiological processes. This chapter aims to provide background information and some history on the various subjects that were involved in this study. The chapter will start out with a brief overview of the discovery of GSLs and the evolving view of the biological role of GSLs and carbohydrate containing biomolecules in general during the last century. Next, the topology and dynamics of mammalian GSL biosynthesis and degradation will be described with special attention for the involved carbohydrate-processing enzymes.
    [Show full text]
  • ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are The
    0031-3998/07/6103-0267 PEDIATRIC RESEARCH Vol. 61, No. 3, 2007 Copyright © 2007 International Pediatric Research Foundation, Inc. Printed in U.S.A. ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are the Predominant FGF Ligands Expressed in Human Fetal Growth Plate Cartilage PAVEL KREJCI, DEBORAH KRAKOW, PERTCHOUI B. MEKIKIAN, AND WILLIAM R. WILCOX Medical Genetics Institute [P.K., D.K., P.B.M., W.R.W.], Cedars-Sinai Medical Center, Los Angeles, California 90048; Department of Obstetrics and Gynecology [D.K.] and Department of Pediatrics [W.R.W.], UCLA School of Medicine, Los Angeles, California 90095 ABSTRACT: Fibroblast growth factors (FGF) regulate bone growth, (G380R) or TD (K650E) mutations (4–6). When expressed at but their expression in human cartilage is unclear. Here, we deter- physiologic levels, FGFR3-G380R required, like its wild-type mined the expression of entire FGF family in human fetal growth counterpart, ligand for activation (7). Similarly, in vitro cul- plate cartilage. Using reverse transcriptase PCR, the transcripts for tivated human TD chondrocytes as well as chondrocytes FGF1, 2, 5, 8–14, 16–19, and 21 were found. However, only FGF1, isolated from Fgfr3-K644M mice had an identical time course 2, 17, and 19 were detectable at the protein level. By immunohisto- of Fgfr3 activation compared with wild-type chondrocytes and chemistry, FGF17 and 19 were uniformly expressed within the showed no receptor activation in the absence of ligand (8,9). growth plate. In contrast, FGF1 was found only in proliferating and hypertrophic chondrocytes whereas FGF2 localized predominantly to Despite the importance of the FGF ligand for activation of the resting and proliferating cartilage.
    [Show full text]
  • Cytokine Nomenclature
    RayBiotech, Inc. The protein array pioneer company Cytokine Nomenclature Cytokine Name Official Full Name Genbank Related Names Symbol 4-1BB TNFRSF Tumor necrosis factor NP_001552 CD137, ILA, 4-1BB ligand receptor 9 receptor superfamily .2. member 9 6Ckine CCL21 6-Cysteine Chemokine NM_002989 Small-inducible cytokine A21, Beta chemokine exodus-2, Secondary lymphoid-tissue chemokine, SLC, SCYA21 ACE ACE Angiotensin-converting NP_000780 CD143, DCP, DCP1 enzyme .1. NP_690043 .1. ACE-2 ACE2 Angiotensin-converting NP_068576 ACE-related carboxypeptidase, enzyme 2 .1 Angiotensin-converting enzyme homolog ACTH ACTH Adrenocorticotropic NP_000930 POMC, Pro-opiomelanocortin, hormone .1. Corticotropin-lipotropin, NPP, NP_001030 Melanotropin gamma, Gamma- 333.1 MSH, Potential peptide, Corticotropin, Melanotropin alpha, Alpha-MSH, Corticotropin-like intermediary peptide, CLIP, Lipotropin beta, Beta-LPH, Lipotropin gamma, Gamma-LPH, Melanotropin beta, Beta-MSH, Beta-endorphin, Met-enkephalin ACTHR ACTHR Adrenocorticotropic NP_000520 Melanocortin receptor 2, MC2-R hormone receptor .1 Activin A INHBA Activin A NM_002192 Activin beta-A chain, Erythroid differentiation protein, EDF, INHBA Activin B INHBB Activin B NM_002193 Inhibin beta B chain, Activin beta-B chain Activin C INHBC Activin C NM005538 Inhibin, beta C Activin RIA ACVR1 Activin receptor type-1 NM_001105 Activin receptor type I, ACTR-I, Serine/threonine-protein kinase receptor R1, SKR1, Activin receptor-like kinase 2, ALK-2, TGF-B superfamily receptor type I, TSR-I, ACVRLK2 Activin RIB ACVR1B
    [Show full text]
  • Katalog 2015 Cover Paul Lin *Hinweis Förderung.Indd
    Product List 2015 WE LIVE SERVICE Certificates quartett owns two productions sites that are certified according to EN ISO 9001:2008 Quality management systems - Requirements EN ISO 13485:2012 + AC:2012 Medical devices - Quality management systems - Requirements for regulatory purposes GMP Conformity Our quality management guarantees products of highest quality! 2 Foreword to the quartett product list 2015 quartett Immunodiagnostika, Biotechnologie + Kosmetik Vertriebs GmbH welcomes you as one of our new business partners as well as all of our previous loyal clients. You are now member of quartett´s worldwide customers. First of all we would like to introduce ourselves to you. Founded as a family-run company in 1986, quartett ensures for more than a quarter of a century consistent quality of products. Service and support of our valued customers are our daily businesses. And we will continue! In the end 80´s quartett offered radioimmunoassay and enzyme immunoassay kits from different manufacturers in the USA. In the beginning 90´s the company changed its strategy from offering products for routine diagnostic to the increasing field of research and development. Setting up a production plant in 1997 and a second one in 2011 supported this decision. The company specialized its product profile in the field of manufacturing synthetic peptides for antibody production, peptides such as protease inhibitors, biochemical reagents and products for histology, cytology and immunohistology. All products are exclusively manufactured in Germany without outsourcing any production step. Nowadays, we expand into all other diagnostic and research fields and supply our customers in universities, government institutes, pharmaceutical and biotechnological companies, hospitals, and private doctor offices.
    [Show full text]
  • SUPPLEMENTAL DATA Supplemental Materials And
    SUPPLEMENTAL DATA Supplemental Materials and Methods Cells and Cell Culture Human breast carcinoma cell lines, MDA-MB-231 and MCF7, were purchased from American Type Tissue Culture Collection (ATCC). 231BoM-1833, 231BrM-2a, CN34, CN34-BoM2d, CN34-BrM2c and MCF7- BoM2d cell lines were kindly provided by Dr. Joan Massagué (Memorial Sloan-Kettering Cancer Center) (1-3). Luciferase-labeled cells were generated by infecting the lentivirus carrying the firefly luciferase gene. The immortalized mouse bone microvascular endothelial cell (mBMEC) was a generous gift from Dr. Isaiah J. Fidler (M.D. Anderson Cancer Center) (4). MCF10A and MCF10DCIS.com cells were purchased from ATCC and Asterand, respectively. MDA-MB-231, its variant cells, MCF7 and MCF-BoM2d cells were cultured in DMEM medium supplemented with 10% FBS and antibiotics. CN34 and its variant cells were cultured in Medium199 supplemented with 2.5% FBS, 10 µg/ml insulin, 0.5 µg/ml hydrocortisone, 20 ng/ml EGF, 100 ng/ml cholera toxin and antibiotics. MCF10DCIS.com cells were cultured in RPMI-1640 medium supplemented with 10% FBS and antibiotics. MCF10A cells were cultured in MEGM mammary epithelial cell growth medium (Lonza). mBMEC was maintained at 8% CO2 at 33 °C in DMEM with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 1% non-essential amino acids and 1% vitamin mixture. Bone marrow stromal fibroblast cell lines HS5 and HS27A, and osteoblast cell line, hFOB1.19, were purchased from ATCC. Bone marrow derived human mesenchymal stem cells, BM-hMSC, were isolated for enrichment of plastic adherent cells from unprocessed bone marrow (Lonza) which was depleted of red blood cells.
    [Show full text]
  • Pathophysiological Roles of FGF Signaling in the Heart
    MINI REVIEW ARTICLE published: 06 September 2013 doi: 10.3389/fphys.2013.00247 Pathophysiological roles of FGF signaling in the heart Nobuyuki Itoh* and Hiroya Ohta Department of Genetic Biochemistry, Kyoto University Graduate School of Pharmaceutical Sciences, Kyoto, Japan Edited by: Cardiac remodeling progresses to heart failure, which represents a major cause of Marcel van der Heyden, University morbidity and mortality. Cardiomyokines, cardiac secreted proteins, may play roles Medical Center, Netherlands in cardiac remodeling. Fibroblast growth factors (FGFs) are secreted proteins with Reviewed by: diverse functions, mainly in development and metabolism. However, some FGFs play Marcel van der Heyden, University Medical Center, Netherlands pathophysiological roles in cardiac remodeling as cardiomyokines. FGF2 promotes cardiac Christian Faul, University of Miami hypertrophy and fibrosis by activating MAPK signaling through the activation of FGF Miller School of Medicine, USA receptor (FGFR) 1c. In contrast, FGF16 may prevent these by competing with FGF2 for the *Correspondence: binding site of FGFR1c. FGF21 prevents cardiac hypertrophy by activating MAPK signaling Nobuyuki Itoh, Department of through the activation of FGFR1c with β-Klotho as a co-receptor. In contrast, FGF23 Genetic Biochemistry, Kyoto α University Graduate School of induces cardiac hypertrophy by activating calcineurin/NFAT signaling without Klotho. Pharmaceutical Sciences, These FGFs play crucial roles in cardiac remodeling via distinct action mechanisms. These Yoshida-Shimoadachi, Sakyo, findings provide new insights into the pathophysiological roles of FGFs in the heart and Kyoto 606-8501, Japan may provide potential therapeutic strategies for heart failure. e-mail: itohnobu@ pharm.kyoto-u.ac.jp Keywords: FGF, heart, hypertrophy, fibrosis, heart failure, cardiomyokine INTRODUCTION mice and humans, respectively.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Recombinant Escheichia Coli-Catalyzed Production of Cytidine 5′-Triphosphate from Cytidine 5′-Monophosphate
    J. Ind. Eng. Chem., Vol. 12, No. 5, (2006) 757-761 Recombinant Escheichia coli-Catalyzed Production of Cytidine 5′-Triphosphate from Cytidine 5′-Monophosphate Sun-Gu Lee† and Byung-Gee Kim* Department of Chemical and Biochemical Engineering, Pusan National University, Busan 609-735, Korea *School of Chemical Engineering, and Institute of Molecular Biology and Genetics, Seoul National University, Seoul 151-742, Korea Received April 24, 2006; Accepted May 22, 2006 Abstract: A recombinant Escherichia coli overexpressing CMP-kinase was constructed and employed as a whole cell biocatalyst for the conversion of cytidine 5′-monophosphate to cytidine 5′-triphosphate. In the whole cell biocatalysis, recombinant CMP kinase catalyzed the conversion of CMP to CDP, and endogenous acetate kinase of the E. coli was utilized for the ATP regeneration as well as for the conversion of CDP to CTP. A conversion yield of ca. 88 % CTP was obtained when starting with 20 mM CMP, 1 mM ATP, and 80 mM acetyl phosphate based on the initial CMP concentration. Endogenous pyruvate kinase and poly- phosphate kinase were inefficient in the process. The CTP production system was applied to the production of CMP-NeuAc by additionally introducing the CMP-NeuAc synthetase gene into the recombinant E. coli. Keywords: CMP-kinase, whole cell biocatalysis, ATP regeneration, cytidine 5′-monophosphate Introduction employing enzymes [4]. They applied various enzymatic 1) methods and chemical methods and concluded that the As glycosyltransferase-catalyzed synthetic techniques enzymatic method based on adenylate kinase/pyruvate are becoming recognized as powerful methods for the kinase provided the most convenient route to CTP. In the preparation of biologically important oligosaccharides, process, CTP was generated efficiently from an inexpen- the development of cost-efficient production methods for sive substrate, CMP.
    [Show full text]
  • Découverte D'une Nouvelle Famille De Protéine Kinases Bactériennes
    Découverte d’une nouvelle famille de protéine kinases bactériennes : mécanismes de fonctionnement et rôle cellulaire de YdiB, un archétype chez Baccillus subtilis Hien-Anh Nguyen To cite this version: Hien-Anh Nguyen. Découverte d’une nouvelle famille de protéine kinases bactériennes : mécanismes de fonctionnement et rôle cellulaire de YdiB, un archétype chez Baccillus subtilis. Sciences agricoles. Université de Grenoble, 2012. Français. NNT : 2012GRENV017. tel-00721757 HAL Id: tel-00721757 https://tel.archives-ouvertes.fr/tel-00721757 Submitted on 30 Jul 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSE Pour obtenir le grade de DOCTEUR DE L’UNIVERSITÉ DE GRENOBLE Spécialité : Chimie-Biologie Arrêté ministériel : 7 août 2006 Présentée par Hien-Anh NGUYEN Thèse dirigée par le Dr. Jean-Michel JAULT préparée au sein de l’Institut de Biologie Structurale J.-P. Ebel, et du CEA de Grenoble dans l'École Doctorale Chimie et Sciences du Vivant Découverte d’une nouvelle famille de protéines kinases bactériennes : Mécanisme de fonctionnement et rôle cellulaire de YdiB, un représentant chez B. subtilis Thèse soutenue publiquement le 23 mai 2012 devant le jury composé de : Mme. Patricia DOUBLET Rapporteur Prof.
    [Show full text]